BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24636429)

  • 1. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).
    Mustafa M; Chan WM; Lee C; Harijanto E; Loo CM; Van Kinh N; Anh ND; Garcia J
    Int J Antimicrob Agents; 2014 Apr; 43(4):353-60. PubMed ID: 24636429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
    Jenkins SG; Fisher AC; Peterson JA; Nicholson SC; Kaniga K
    Curr Med Res Opin; 2009 Dec; 25(12):3029-36. PubMed ID: 19849650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
    Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
    Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii].
    Taşbakan MS; Pullukçu H; Ekren PK; Oz AT; Midilli M; Aydemir S; Gürgün A; Başoğlu OK; Bacakoğlu F
    Mikrobiyol Bul; 2009 Jan; 43(1):61-70. PubMed ID: 19334381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
    Lu Q; Luo R; Bodin L; Yang J; Zahr N; Aubry A; Golmard JL; Rouby JJ;
    Anesthesiology; 2012 Dec; 117(6):1335-47. PubMed ID: 23132092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors.
    Chaari A; Mnif B; Bahloul M; Mahjoubi F; Chtara K; Turki O; Gharbi N; Chelly H; Hammami A; Bouaziz M
    Int J Infect Dis; 2013 Dec; 17(12):e1225-8. PubMed ID: 24094525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
    Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial infections in a medical-surgical intensive care unit.
    Aly NY; Al-Mousa HH; Al Asar el SM
    Med Princ Pract; 2008; 17(5):373-7. PubMed ID: 18685276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.
    Urban C; Mariano N; Rahal JJ
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2732-4. PubMed ID: 20368401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
    Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
    Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
    Arnold HM; Sawyer AM; Kollef MH
    Respir Care; 2012 Aug; 57(8):1226-33. PubMed ID: 22349038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nosocomial infection characteristics in a burn intensive care unit: analysis of an eleven-year active surveillance.
    Öncül O; Öksüz S; Acar A; Ülkür E; Turhan V; Uygur F; Ulçay A; Erdem H; Özyurt M; Görenek L
    Burns; 2014 Aug; 40(5):835-41. PubMed ID: 24296064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia.
    Cannavino CR; Castaneda-Ruiz B; Redman R; Go O; Cirillo I; Barauskas V; Senatorova G; Emeryk A; Bradley JS
    Pediatr Infect Dis J; 2015 Nov; 34(11):1264-7. PubMed ID: 26226440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.